Genetic editing holds promise to treat incurable diseases, but the most popular method—CRISPR—sometimes does more harm than ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Fintel reports that on September 18, 2025, JP Morgan initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Overweight recommendation. Analyst Price Forecast Suggests 37.35% Upside As of ...

A study using CRISPR restored brain connectivity and made the brain more resilient to seizures, which are often seen in a ...

Horses with genomic edits to make them run faster have been banned from polo, but a zoo of CRISPR-edited animals is gaining ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59.07, marking a -3.46% move from the previous day.

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing ...

CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

Genetic editing holds promise to treat incurable diseases, but the most popular method - CRISPR - sometimes does more harm ...

The evolutionary blueprint for hands was borrowed in part from a much older genetic plan for our nether regions, a new study ...